Your browser doesn't support javascript.
loading
[Interest of reTURB for pTa high grade bladder urothelial carcinoma]. / Intérêt de la résection complémentaire (ou « second look ¼) pour les carcinomes urothéliaux de vessie classés pTa haut grade.
Branchu, B; Léon, P; Jeglinschi, S C; Durlach, A; Trigui, S; Birembaut, P; Larré, S.
Afiliação
  • Branchu B; Service d'urologie, CHU de Reims, 51000 Reims, France. Electronic address: bbranchu@chu-reims.fr.
  • Léon P; Service d'urologie, clinique Pasteur, 17200 Royan, France.
  • Jeglinschi SC; Service d'urologie, CHU de Nice, 06000 Nice, France.
  • Durlach A; Laboratoire d'anatomopathologie, CHU de Reims, 51000 Reims, France.
  • Trigui S; Service d'urologie, Polyclinique Montier-la-celle, 10120 Saint-André-les-Vergers, France.
  • Birembaut P; Laboratoire d'anatomopathologie, CHU de Reims, 51000 Reims, France.
  • Larré S; Service d'urologie, CHU de Reims, 51000 Reims, France.
Prog Urol ; 30(1): 19-25, 2020 Jan.
Article em Fr | MEDLINE | ID: mdl-31866142
ABSTRACT

INTRODUCTION:

Second look TURB (Transurethral Resection of Bladder Tumor) is recommended for high-risk pT1 tumors. It is well acquired for tumors classified pT1 high grade but its interest is still discussed for high-grade pTa tumors in the absence of high level of evidence. We evaluated the impact of second-look resection for the high-grade pTa bladder tumor.

METHODS:

We performed a retrospective study in 2 centers from 2007 to 2016. We included all urothelial tumors classified pTa high grade. We studied the anatomopathological findings of reTURB and its consequences on survival without recurrence and progression.

RESULTS:

Eighty-four patients were included. Thirty-five patients (41.7%) had reTURB and residual tumor was found in 42.9% of cases. The anatomopathology of reTURB was in 20% of cases high grade pTa, in 14.3% of cases pTis, and in 8.6% of cases pT1. Forty-three patients had recurrence, 13 reTURB patients (30.2%). In the patients who had a reTURB, 12 had recurrence (34.3%) against 31 without reTURB, (63.3%). After the first TURB, 45 patients (53.6%) had bladder instillation 38 received BCG (45.2%) and 7 ametycin (8.3%). The main factor decreasing recurrence was BCG adjuvant therapy (HR=0.4 [0.2-0.9], P=0.02). The absence of reRTUV appeared to be a recurrence factor, but the result was not statistically significant (HR=1.4 [0.7-3], P=0.3).

CONCLUSION:

reTURB confirms that residual tumor is often found. His interest in survival without recurrence remains to be proved by a prospective study with a larger number of patients. LEVEL OF EVIDENCE 3.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Procedimentos Cirúrgicos Urológicos / Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: Fr Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Procedimentos Cirúrgicos Urológicos / Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: Fr Ano de publicação: 2020 Tipo de documento: Article